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Background: Chronic kidney disease (CKD) patients requiring intravenous vancomycin 
bear considerable risks of adverse outcomes both from the infection and vancomycin 
therapy itself, necessitating especially precise dosing to avoid sub- and supratherapeutic 
vancomycin exposure.
Methods: In this retrospective study, we performed a population pharmacokinetic analysis 
to construct a vancomycin dose prediction model for CKD patients who do not require renal 
replacement therapy. The model was externally validated on an independent cohort of patients 
to assess its prediction accuracy. The pharmacokinetic parameter estimates and the equations 
were productized into a Web application (VancApp) subsequently implemented in routine 
care. The association between VancApp-based dosing and time-to-target concentration 
attainment, 30-day mortality, and nephrotoxicity were assessed postimplementation.
Results: The model constructed from an initial cohort (n = 80) revealed a population 
clearance and volume of distribution of 1.30 L/h and 1.23 L/kg, respectively. External 
model validation (n = 112) demonstrated a mean absolute prediction error of 1.25 mg/L. 
Following 4 months of clinical implementation of VancApp as an optional alternative to 
usual care [VancApp (n = 22) vs. usual care (n = 21)], patients who had received VancApp-
based dosing took a shorter time to reach target concentrations (median: 66 vs. 102 h, p = 
0.187) and had fewer 30-day mortalities (14% vs. 24%, p = 0.457) compared to usual 
care. While statistical significance was not achieved, the clinical significance of these 
findings appear promising.
Conclusion: Clinical implementation of a population pharmacokinetic model for 
vancomycin in CKD can potentially improve dosing precision in CKD and could serve as 
a practical means to improve vital clinical outcomes.
Keywords: population pharmacokinetics, vancomycin, chronic renal failure, prediction modelling, precision medicine
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INTRODUCTION
Treatment success with intravenous vancomycin hinges on 
timely and accurate attainment of target drug exposure (Hidayat 
et al., 2006; Martinez et al., 2012). Despite decades of clinical 
experience, accurate dosing of vancomycin remains challenging 
in situations of altered pharmacokinetics. Chronic kidney disease 
(CKD) alters both the volume of distribution (Vd) and clearance 
of vancomycin, predisposing patients to dosing inaccuracies 
which lead to delayed target exposures (Jeffres et al., 2007; 
Matzke et al., 2011). Inaccurate dosing is particularly hazardous 
in CKD patients with serious methicillin-resistant Staphylococcus 
aureus (MRSA) infections because CKD is independently 
associated with an elevated mortality risk (Pastagia et al., 2012). 
While aggressive treatment may thus be warranted in such 
scenarios, vancomycin-associated nephrotoxicity is also more 
likely to occur in patients with preexisting renal impairment 
(Panwar et al., 2013). Therefore, precise dosing plays a pivotal 
role in maximizing treatment success in CKD patients requiring 
intravenous vancomycin.
However, there remains a lack of models specifically designed 
for dosing vancomycin in CKD (Moellering et al., 1981; Matzke 
et al., 1984; Rodvold et al., 1988; Rybak et al., 2009; Thomson et al., 
2009; Cardile et al., 2015). Although the area under the curve 
to minimum inhibitory concentration ratio (AUIC) is gaining 
popularity as the preferred parameter of efficacy, models that 
optimize troughs may be still useful in settings where the minimum 
inhibitory concentrations (MICs) are ≤1 mg/L. Typically, trough 
concentrations of 15 mg/L are able to achieve AUICs that exceed 
the target threshold of 400 mg h/L in these scenarios (Rybak 
et al., 2009; Pai et al., 2014). In this study, we propose a model for 
optimizing vancomycin therapy with a retrospective study based 
on trough concentrations in CKD. Additionally, we retrospectively 
evaluate the clinical impact of model-based dosing on clinical 
outcomes following implementation in routine care (Dorajoo and 
Chan, 2017).
MATERIALS AND METHODS
Study Overview, Design, and Setting
This study was carried out in three phases. The first phase 
involved model construction and internal validation, the 
second phase involved external model validation and Web 
application development, and the third phase involved model 
implementation and postimplementation evaluation. The results 
of each phase motivated subsequent phases of the study. All study 
phases were approved by the Domain Specific Review Board, 
with a waiver of informed consent. All phases of the study were 
conducted at Khoo Teck Puat Hospital (KTPH), Singapore—a 
600-bed tertiary healthcare institution providing a wide range of 
medical and surgical specialty services.
Phase 1: Model Derivation and Internal 
Validation
Model derivation was performed by extracting records of patients 
who had received intravenous vancomycin from 1st April 2013 to 
31st March 2014. An in-house vancomycin protocol is routinely 
used to dose intravenous vancomycin. Briefly, weight-based 
doses of 15–20 mg/kg are administered at intervals of 12 or 24 h 
and infused at a maximum rate of 500 mg/h. A maximum dose of 
2 g is administered per infusion, regardless of total body weight. 
The vast majority of MRSA isolates exhibit a vancomycin MIC of 
1 mg/L at KTPH.
Inclusion/Exclusion Criteria and Data Collection
Patients were included if they had received at least two doses 
of intravenous vancomycin over a 72-h period, had a baseline 
creatinine clearance (CrCl) of less than 60 ml/min based on the 
Cockcroft–Gault equation using total body weight (to mirror 
actual clinical practice), and at least one measured vancomycin 
concentration. Patients were excluded if they were receiving 
renal replacement therapy, had no documented weight or 
serum creatinine measured at baseline, or if they had previously 
received intravenous vancomycin less than 2 weeks before 
the date of therapy initiation. Details of the dosing regimen 
administered for the first 5 days of therapy were collected. The 
list of potential covariates which could influence the clearance 
and Vd of vancomycin is provided as Supplementary Material 
(Jelliffe, 1973; Levey et al., 1999; Levey et al., 2009).
Model Derivation
A population pharmacokinetic (PopPk) analysis was performed 
in NONMEM version 7.3. A first-order conditional estimation 
method with interactions (FOCE-I) was employed for the model 
building process (Wahlby et al., 2001; Wahlby et al., 2002). The 
interindividual variability (IIV) in the model was determined 
by exponential random effects, while the residual variability 
was modelled as a mixture of additive and proportional error 
structures. Stepwise univariate forward selection followed 
by backward elimination was used in covariate selection. 
Details of the covariate selection procedure are provided as 
Supplementary Material.
Internal Validation
Internal model validity was assessed via visual inspection of the 
scatter plots of plasma concentrations versus population prediction 
(PRED) and individual predicted (IPRED) concentrations. The 
relative prediction errors were graphically described by conditional 
weighted residuals (CWRES) and plotted against PRED and time 
after dose. One thousand bootstrapped datasets were generated 
via repeated random sampling with replacement to evaluate the 
stability of the estimates of the final model (Ette, 1997).
Phase 2: External Validation Web 
Application Development
External validation was performed on a separate group of CKD 
patients who had received intravenous vancomycin from 1st 
April 2014 to 31st March 2015. The model was used to predict 
the observed vancomycin concentrations in the external cohort. 
Mean absolute error (MAE), mean squared error (MSE), and root 
mean square error (RMSE) were used to evaluate model accuracy.
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A model with an MAPE of less than 30% was arbitrarily 
considered to be clinically acceptable (Zhao et al., 2016). 
Additionally, differences between observed and predicted 
concentrations were visually assessed using the Bland–Altman plot.
The model was subsequently productized into two Web 
applications (VancApp) to facilitate point-of-care decision-
making, for initial dosing and subsequent dose adjustments. 
VancApp was designed to allow clinicians the flexibility of 
selecting appropriate loading and maintenance dose pairs for a 
given patient and to visualize the simulated concentration–time 
profile (Wojciechowski et al., 2015).
Phase 3: Clinical Implementation 
and Impact Assessment
Clinical Implementation and Usage Protocol
VancApp fulfilled the criteria for quality improvement projects/
clinical services specified by the Domain Specific Review Board 
and was approved for use by the hospital Medical Board in August 
2016. VancApp was implemented in routine care in September 
2016. Usage of VancApp followed the prevailing safety guidances 
as per the in-house dosing protocol (i.e., a maximum of 30 mg/kg 
for loading and 20 mg/kg for maintenance doses, administered 
at a maximum rate of 500 mg/h). VancApp’s implementation 
was made known to all medical and surgical teams via weekly 
multidisciplinary departmental meetings.
VancApp was integrated into the clinical workflow by engaging 
ward pharmacists who screened and evaluated VancApp usage 
eligibility. VancApp was only used in patients with a CrCl less than 
60 ml/min. All pharmacists had undergone two training sessions on 
the appropriate use of VancApp in August 2016. Briefly, pharmacists 
were trained to enter the required parameters (age, gender, serum 
creatinine, and total body weight) to determine the most appropriate 
loading (if applicable) and maintenance dose pair. VancApp-based 
dose recommendations were then communicated to the primary 
team who could choose to defer from the recommendation. 
Pharmacists electronically documented VancApp usage to facilitate 
monitoring and automated data retrieval.
Usual Care Dosing
In the usual care group, patients were dosed according to the 
in-house dosing protocol at KTPH where clinical teams had 
chosen not to accept the VancApp dose. Typically patients with 
mild to moderate skin/soft tissue infections (SSTIs) as well as 
urinary tract infections are dosed at 10 to 15 mg/kg. Doses of 
15 to 20 mg/kg are used to treat pneumonia, sepsis, bacteremia, 
osteomyelitis, meningitis, and severe SSTIs as per the in-house 
protocol (Rybak et al., 2009).
Clinical Impact Assessment
To assess the impact of VancApp-based dosing, we retrospectively 
reviewed patients who received vancomycin from November 
2016 to February 2017. Baseline demographics, laboratory test 
data, comorbidities, indication of vancomycin, and concomitant 
nephrotoxin exposure were assessed. The primary outcome was 
the time to reach the first therapeutic target trough. Secondary 
outcomes were the length of hospitalization, 30-day mortality, 
30-day readmission due to MRSA infections, and vancomycin-
associated nephrotoxicity (defined as a 50% or greater increase 
in serum creatinine).
The time to attain the first target trough was compared using 
the Kaplan–Meier estimator and the log rank test was used to 
assess for differences. Differences in secondary outcomes were 
tested using the Mann–Whitney U and Fisher’s exact test where 
appropriate.
RESULTS
Phase 1: Model Derivation and Internal 
Validation
The derivation cohort comprised of 80 patients who had a mean ± 
standard deviation (SD) CrCl of 33.8 ± 10.3 ml/min and total body 
weight (TBW) of 57.8 ± 15.7 kg. Seventy-five percent of patients 
were at CKD stage 3 and beyond. Other demographic and clinical 
parameters of patients are summarized by cohort in Table 1. In 
total, 170 vancomycin concentrations were acquired over the initial 
120 h of therapy, amounting to an average of 2.1 ± 1.3 (range: 1–4) 
concentrations per patient. From the time of dose administration, 
there was at least one sample acquired every 2 h from one or more 
patients, up to the 50th hour following dose administration.
Population Pharmacokinetic Model
A one-compartment model was preferentially selected to describe 
our data (justification provided as Supplementary Method). The 
parameter estimates of the final model are presented in Table 2, 
demonstrating a population clearance of 1.30 L/h [relative 
standard error (RSE): 7%]. The population Vd was 1.23 L/kg 
(RSE: 5%). CrCl significantly influenced the clearance variability 
of vancomycin (Supplementary Figures S1 and S2). All other 
potential covariates tested were insignificant.
Scatter plots of observed versus predicted concentrations 
using the final model are shown in Figure 1A and B, respectively. 
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The inclusion of IIV reduces the dispersion of observed versus 
predicted concentrations around the line of identity. Visual 
inspection of the CWRES versus population predictions and time 
after dose suggested an absence of model misspecification, with 
more than 95% of residuals falling within −2 and 2 (Figure 1C 
and D). The consistency estimates from bootstrapping suggested 
that the final model provided a satisfactory description of the 
data used for model construction (Table 2).
Phase 2: External Validation and Web 
Application Development
The validation cohort consisted of 112 separate patients with a mean 
CrCl of 35.5 ± 13.6 ml/min and TBW of 58.7 ± 14.1 kg. As with 
patients in the derivation cohort, three quarters of the validation 
cohort comprised of patients in CKD stage 3 and beyond. Other 
demographic and clinical parameters were comparable (Table 1). 
A total of 289 vancomycin concentrations were acquired over 
the initial 120 h of therapy, amounting to an average of 2.3 ± 1.3 
(range: 1–5) concentrations. The model had a MAE of 1.25 mg/L 
and a MSE of 1.78 (mg/L)2 when used to predict 289 observed 
concentrations in the validation cohort (other validation metrics 
provided in Supplementary Table 1).
Figure 2 is a Bland–Altman plot depicting the degree 
of agreement between observed and individual predicted 
concentrations on validation, illustrating that the vast majority of 
the differences between observed and predicted concentrations 
fall within ± 2 standard deviations (limits of agreement) of the 
mean difference. The differences between observed and predicted 
concentrations appeared consistent over the range of average 
concentration levels and there was no clear evidence of proportional 
error in the plot. Visual inspection of the Visual Predictive Check 
(VPC) plot is provided in Supplementary Figure S3. The VPC 
indicates that the 95% confidence band captures most of the 
observed concentration in the validation cohort.
Considering the results of external validation in totality, the 
model was deemed sufficiently accurate and precise to consider 
progression into the next phases of productization and clinical 
implementation.
The productized final models (VancApp) can be accessed at 
http://bit.ly/vancapp_initial and at http://bit.ly/vancapp_adjust 
for initial dosing and post-trough adjustments, respectively 
(Supplementary Figure S4). Initial dosing decisions were 
individualized and heavily depended upon patient factor such as 
illness severity (to determine loading dose requirement) as well 
as factors that could significantly affect PK parameters including 
creatinine clearance, total body weight, age, and gender. Care 
teams comprising of physicians and pharmacists had undergone 
briefing sessions on iteratively adjusting doses and dosing intervals 
that led to trough concentrations that they were intending to 








1st April 2014 – 31st 
March 2015
Sex, n (%)
 Male 51 (63.7) 71 (63.4)
 Female 29 (36.3) 41 (36.6)
Age, years, mean ± SD 71.7 ± 13.0 73.5 ± 12.5
Total body weight (kg), 
mean ± SD
57.8 ± 15.7 58.7 ± 14.1
Height (m), mean ± SD 1.59 ± 0.08 1.60 ± 0.10
Body mass index (kg/m2), 
mean ± SD
22.6 ± 5.9 22.7 ± 4.7
Body surface area (m2), 
mean ± SD
1.58 ± 0.23 1.61 ± 0.22
Serum creatinine (µmol/L), 
mean ± SD
150.6 ± 73.6 151.1 ± 83.1
Creatinine clearance* 
(ml/min/1.73 m2), mean ± SD
33.8 ± 10.3 35.5 ± 13.6
Estimated glomerular filtration 
rate^ (ml/min/1.73 m2), 
mean ± SD
46.2 ± 23.0 48.9 ± 28.8
Chronic kidney disease stage^, n (%)
 CKD 1 (≥90 ml/min/1.73 m2) 5 (6.3) 14 (12.5)
 CKD 2 (60–89 ml/min/1.73 m2) 15 (18.8) 14 (12.5)
 CKD 3a (45–59 ml/min/1.73 m2) 18 (22.5) 23 (20.5)
 CKD 3b (30–44 ml/min/1.73 m2) 20 (25.0) 29 (25.9)
 CKD 4 (15–29 ml/min/1.73 m2) 19 (23.8) 26 (23.2)
 CKD 5 (<15 ml/min/1.73 m2) 3 (3.8) 6 (5.3)
Serum albumin (g/L), mean ± SD 27.3 ± 6.7 27.1 ± 6.0
C-reactive protein (mg/L), 
mean ± SD
102.0 ± 81.9 122.4 ± 95.9
Procalcitonin (ng/ml), mean ± SD 10.1 ± 16.8 26.5 ± 16.0
Total white blood cell count, 
mean ± SD
13.76 ± 8.09 13.87 ± 6.36
Neutrophil percentage (%), 
mean ± SD
83.9 ± 9.9 83.4 ± 9.9
*Calculated using Cockcroft–Gault equation, based on total body weight.
^Calculated using Modification of Diet in Renal Disease equation (Levey et al., 2007).
SD, standard deviation.
TABLE 2 | Population parameter estimates of the final model.
Parameter Final estimate RSE% Shrinkage% Bootstrap estimate 95% Confidence 
interval
Cl (L/h) 1.30 7.2 – 1.30 (1.18–1.60)
θCrCl 0.023 24.2 – 0.023 (0.011–0.033)
Vd (L/kg) 1.23 4.9 – 1.23 (1.12–1.37)
ηCl (%) 54.4 10.2 12.0 53.8 (41.2–65.5)
ηVd (%) 22.5 17.1 26.0 21.9 (12.6–29.3)
Additive error (mg/L) 2.46 12.3 – 2.44 (1.85–2.98)
Proportional error (σ2) 0.001 – – – –
RSE, Relative standard error.
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attain for their patient. Alternatively, clinicians could also assess 
their planned prior dosing regimen and evaluate the simulated 
concentration–time profile of vancomycin in their patient and 
amend it accordingly. Based on our in-house vancomycin protocol, 
more frequent trough monitoring is recommended in patients with 
renal impairment but this decision is typically left to the team’s 
discretion who may decide to monitor trough concentrations more/
less frequently given individual patient circumstances. Following 
this trough measurement, dose adjustments may or may not be 
warranted using the adjustment module of the app, depending on 
the urgency to attain target concentrations.
The code to generate the initial dosing application is also 
provided as Supplementary Material (Supplementary R code).
Phase 3: Clinical Implementation 
and Real-World Impact Assessment
A total of 256 patients received vancomycin between September 
2016 and January 2017, of whom 54 were included for analysis. 
Twenty-two patients (41%) were dosed using VancApp from 
time of vancomycin initiation. Twenty-one patients (39%) were 
dosed according to usual care based on the in-house protocol. 
The remaining 11 patients (20%) had switched to VancApp-
based dosing after initially receiving doses based on usual care 
(Supplementary Figure S5). The VancApp group and the usual 
care group had comparable gender ratios, age, total body weight, 
CrCl, and proportion of patients at various CKD stages. All other 
demographic parameters are compared in Table 3. No significant 
differences in terms of baseline characteristics were observed 
between the two groups.
Difference in Time-to-Target Trough Concentrations
Figure 3 illustrates superimposed Kaplan–Meier curves for time 
taken to reach the first therapeutic vancomycin concentration within 
the target range of 10 to 15 or 15 to 20 mg/L. The median time to 
attain the first target trough was 66 h for the VancApp group versus 
102 h in the usual care group. After 72 h of vancomycin therapy, 
70% of the VancApp group had at least one trough within target, 
compared to 30% in the usual care group. These differences, however, 
did not attain statistical significance (log-rank test: p = 0.129).
FIGURE 1 | Scatter plots of (A) observed versus population predictions and (B) individual predictions of vancomycin concentrations using the final model. Scatter 
plots of conditional weighted residuals versus (C) population predictions and (D) time.
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Differences in Clinical Outcomes
The clinical outcomes of patients are summarized in Table 4 by 
group. In light of the small sample, only unadjusted estimates are 
presented. The VancApp group had a higher mean (SD) length 
of hospitalization of 22.5 (10.7) days compared to the usual care 
group of 17.3 (8.4) days (p = 0.197). The VancApp group had a 
lower 30-day mortality (n = 3, 14%) than the usual care group (n = 
5, 24%) (p = 0.457). None of the patients in the model-based group 
required 30-day readmission due to MRSA infection, whereas two 
patients (10%) dosed according to usual care were readmitted (p = 
0.114). There were two patients (9%) who developed nephrotoxicity 
in the VancApp group versus one patient on usual care (5%). 
Notably, the VancApp group received a mean vancomycin dose of 
22.4 ± 3.2 mg/kg/day compared to 27.7 ± 4.1 mg/kg/day in the 
usual care group. All three patients who developed nephrotoxicity 
had received concomitant piperacillin–tazobactam.
Prediction Accuracy of VancApp
On implementation, 78 vancomycin trough concentrations were 
obtained from the 33 patients who had received VancApp-based 
dosing. VancApp demonstrated a MAE of 3.65 mg/L and RMSE 
of 4.62 mg/L (Table 4) in this group.
DISCUSSION
CKD patients requiring intravenous vancomycin are at a 
pronounced risk of succumbing to adverse outcomes from both the 
infection as well as from inappropriate doses of vancomycin itself. 
Precise dosing of vancomycin in CKD is thus needed to maximize 
treatment success. We constructed a population pharmacokinetic 
model (Phase 1) for dosing vancomycin in CKD and retrospectively 
validated it in a separate cohort of CKD patients (Phase 2). The 
model was subsequently productized into a Web application 
(VancApp) and offered in routine practice. In Phase 3, we evaluated 
the impact of the VancApp-based dosing on key clinical outcomes. 
Our findings suggest that VancApp-based dosing can accelerate 
target exposures, potentially improving 30-day mortality and 
30-day readmission due to MRSA infections.
The estimated population Vd of 1.30 L/kg of the model is 
larger than most previous estimates that have ranged between 
0.4 and 1.0 L/kg, but still comparable to that identified in other 
PopPk analyses that had included CKD patients as part of their 
study population (Llopis-Salvia and Jimenez-Torres, 2006; del 
Mar Fernandez de Gatta Garcia et al., 2007; Rybak et al., 2009). 
Thomson et al. (2009) used a two-compartment model and 
estimated the Vd of the central and peripheral compartments to 
be 0.675 and 0.732 L/kg, respectively (steady state Vd = 1.41 L/kg), 
on a cohort consisting of patients with and without CKD having 
a median age of 66 years (range: 16 to 97 years) and a median 
total body weight of 72 kg (range: 40 to 159 kg). Although our 
estimated Vd is similar, our cohort consisted of older (median: 
75 years, range: 31 to 97 years) and lighter (median: 55.8 kg, range: 
33.6–103.8 kg) patients. Besides age-related changes, the higher 
Vd could be attributed to chronic inflammation in CKD due to 
proinflammatory cytokine production, hypoalbuminemia, and 
acidotic conditions in addition to infection-related alterations 
(Tonelli et al., 2005; Verbeeck and Musuamba, 2009; Dungey et 
al., 2013; Akchurin and Kaskel, 2015).
Using the derived parameters and the availability of 
computational resources at the point-of-care, VancApp offers 
the ability to simulate and visualize concentration–time profiles 
for selected doses in individual patients. It therefore facilitates 
precise dose adjustments, providing suggestions to relevant 
questions such as how long doses should be withheld if troughs 
are supratherapeutic and by how much should doses be increased 
by if subtherapeutic.
Patients dosed with VancApp attained target concentrations 
approximately 36 h earlier compared to patients dosed by usual 
care. Timeliness of target trough attainment is an important 
FIGURE 2 | Bland–Altman plot of agreement between the observed and individual predicted concentrations in the temporal validation cohort (n = 112, 289 concentrations).
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surrogate for treatment success particularly in CKD, which 
prolongs the time needed to attain steady-state concentrations 
because of the longer half-life owing to slower clearance. Renal 
impairment independently raises mortality risk in severe 
infections such as MRSA bacteremia (Pastagia et al., 2012). It is 
therefore imperative to optimize doses of vancomycin in CKD 
patients to maximize treatment success. To this end, the model 
demonstrates potential for considerable clinical impact by 
potentially shortening the time to attain target concentrations 
and therefore target exposures.
Rapid attainment of initial target troughs is known to be 
associated with a decrease in readmission and mortality, which 
our findings also seem to suggest (Aliberti et al., 2011). MRSA 
infections have been associated with mortality rates of 20–30% 







Male 12 (55) 16 (76) 0.243
Female 10 (46) 5 (24)
Age, years, mean ± SD 73.5 ± 11.2 70.4 ± 13.9 0.584
Total body weight (kg), mean ± SD 60 ± 15.0 57.3 ± 12.9 0.576
Height (m), mean ± SD 160.0 ± 8.4 161.7 ± 6.2 0.478
Body Mass Index (kg/m2), mean ± SD 23.2 ± 4.3 21.7 ± 4.1 0. 274
Serum creatinine (µmol/L), mean ± SD 168.4 ± 113.5 198.1 ± 141.1 0.481
Creatinine clearance* (ml/min), mean ± SD 33.5 ± 12.0 31.4 ± 14.5 0.544
Estimated glomerular filtration rate^ (ml/min), mean ± SD 46.5 ± 25.6 46.5 ± 28.6 0.895
Intensive care unit admission, n (%) 3 (14) 4 (20) 0.631
Chronic kidney disease stage^, n (%)
0.645 CKD 1 1 (5) 2 (10)
 CKD 2 5 (23) 6 (29)
 CKD 3a 3 (14) 2 (10)
 CKD 3b 8 (36) 3 (14)
 CKD 4 2 (9) 4 (19)
 CKD 5 3 (14) 4 (19)
Comorbidities
Diabetes 9 (40) 7 (30)  0.607
Hypertension 12 (55) 10 (50) 0.650
Malignancy 2 (9) 2 (10) 0.961
Gastrointestinal 3 (14) 2 (10) 0.674
Pulmonary 3 (14) 4 (20) 0.631
Cardiovascular 8 (40) 11 (50) 0.290
Central nervous system 3 (14) 5 (24) 0.391
Type of infection, n (%)
Urinary tract infection 3 (14) 3 (14) 0.951
Community acquired pneumonia 2 (9) 6 (29) 0.116
Hospital acquired pneumonia 3 (14) 4 (19) 0.631
Soft tissue and/or skin infection 9 (40) 4 (19) 0.131
Sepsis 2 (9) 4 (19) 0.378
Bacteremia 1 (5) 3 (14) 0.335
Pyrexia of unknown origin 2 (9) 1 (5) 1.000
CNS infection 1 (5) 0 (0) 1.000
Osteomyelitis 2 (9) 0 (0) 0.488
Cholangitis 1 (5) 0 (0) 1.000
Concurrent antimicrobials
β-lactams
Piperacillin-tazobactam 10 (48) 12 (57) 0.443
Amoxicillin-clavulanate 8 (38) 4 (19) 0.310
Ceftazidime 3 (14) 2 (10) 1.000
Carbapenems 6 (29) 6 (29) 0.924
Floroquinolones 1 (5) 1 (5) 1.000
Aminoglycosides 5 (24) 6 (29) 0.660
Others 5 (24) 6 (29) 0.660
Concurrent nephrotoxins
Vasopressors 3 (14) 3 (14) 1.000
Diuretics 6 (29) 7 (33) 0.665
ACE inhibitors/ARBs 5 (24) 6 (29) 0.660
NSAIDs 2 (9) 3 (14) 0.664
^Calculated using Modified Diet Renal Disease equation.
SD, standard deviation.
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(Moise-Broder et al., 2004; Soriano et al., 2008). Our findings 
suggest that VancApp-based dosing potentially reduces 30-day 
mortality, from 24% to 14%. While not statistically significant, 
this was observed despite the relatively older group of patients 
in our study population [median (interquartile range): 74 (16)], 
given that age is known predictor of mortality in MRSA infections 
(Gasch et al., 2013).
Likewise, readmission due to MRSA infections is an 
undesirable outcome. Besides the development of resistance and 
treatment failure, readmissions inevitably add to the demand for 
hospitalized care, unnecessarily burdening healthcare resources 
(Hidayat et al., 2006; Moise et al., 2007; Soriano et al., 2008). 
Readmissions may be indicative of incomplete bacteriological 
cure during the preceding admission, which could be related to 
dosing imprecision and delays in target attainment. The absence 
of 30-day readmissions in the VancApp group could be attributed 
to earlier target trough attainment. However, we note that there 
was a signal toward increased length of hospitalization in the 
app-based dosing arm. While the longer hospitalization may be 
explained partly by the lower mortality which indirectly implies 
that patients may be alive for a longer period, this remains to be 
studied more closely in a larger, prospective follow-up study.
Nonetheless, the observed improvements in clinical outcomes 
of 30-day readmission and 30-day mortality had occurred without 
a substantial rise in nephrotoxicity with vancomycin use in CKD 
patients, who are more vulnerable toward nephrotoxicity with 
vancomycin use [n = 2 (9%) in the model-based group versus 
n  =  1 (5%) in the usual care group]. While the one additional 
case of nephrotoxicity in the model-based group was observed, 
patients who received model-based doses had received lower 
FIGURE 3 | Kaplan–Meier curve comparing time to first therapeutic target between the model-based group (n = 22) and usual care group (n = 21).
TABLE 4 | Clinical outcomes of patients receiving VancApp-based dosing (n = 22) and patients dosed according to usual care (n = 21), as well as prediction accuracy 
of the model (n = 33, 78 concentrations).
VancApp-based dosing Usual care-based dosing P-value
Clinical outcomes (n = 22) (n = 21)
Nephrotoxicity, n (%) 2 (9) 1 (5) 1.000
Length of hospitalization (days), mean ± SD 22.5 ± 10.7 17.3 ± 8.40 0.197
30-day mortality, n (%) 3 (14) 5 (24) 0.457
30-day readmission, n (%) 0 (0) 2 (10) 0.114
Prediction accuracy (n = 33*)
Mean absolute error 3.65 – –
Mean squared error 21.33 – –
Root mean squared error 4.62 – –
Mean absolute prediction error (%) 32.87 – –
*11 additional patients switched over to VancApp-based dosing mid-way through treatment period.
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vancomycin doses overall (by approximately 5 mg/kg) compared 
to usual care. All three patients who developed nephrotoxicity 
were receiving concomitant piperacillin–tazobactam, which may 
exacerbate nephrotoxicity risks (Burgess and Drew, 2014). The 
nephrotoxicity rates in this study are within literature reported 
rates, ranging between 5% and 25% (Iwamoto et al., 2003; 
Hazlewood et al., 2010).
The strengths of this study include the validation assessment 
conducted in an independent cohort of patients and an evaluation 
of the productized model on important clinical outcomes 
following implementation. These data are lacking in the clinical 
pharmacokinetic literature. This study also demonstrates the 
value the population pharmacokinetic method. Nonetheless, this 
study has a number of limitations. Firstly, our initial analysis was 
based on retrospective data predominantly comprising of trough 
concentrations. Measuring peak vancomycin concentrations has 
been discouraged because of its poor correlation with clinical 
outcomes and is therefore rarely measured in our practice (Rybak 
et al., 2009). Although the estimated Vd appears to be reasonable 
for the CKD population, sparse sampling of peak concentrations 
in our study could have led to misspecification of the Vd as well 
as a preferential fit of a one-compartment model. However, 
the external validation and the postimplementation evaluation 
findings suggest that deep pharmacokinetic characterization 
may not be absolutely necessary to derive models that may yield 
clinical benefit. However, this warrants future investigation. 
Secondly, trough-based dose optimization can lead to higher-
than-necessary vancomycin exposures which could inadvertently 
predispose patients toward vancomycin-related toxicities (Neely 
et al., 2014). Modern dose optimization methods based on 24-h 
area under the concentration–time curve to MIC (AUC/MIC 
ratio) may alter the way vancomycin is dosed in future (Pai et al., 
2014). Nonetheless, inasmuch as trough-based dose optimization 
are still used because of their simplicity and familiarity, our 
findings are likely to have immediate practice implications.
Thirdly, this study did not monitor the extent and number of 
dose adjustments, frequency of dosage adjustments, and trough 
monitoring in the usual care arm to compare these criteria 
between the app-based dosing and usual care which have been 
considered and compared in previous studies (Cardile et al., 
2015; Miller et al., 2018). While a more rapid attainment of target 
trough concentrations may indirectly indicate a reduced need for 
frequent adjustments and monitoring as suggested in Cardile et al. 
who studied an adult population, the same trends were not seen 
in Miller et al. who studied individualized vancomycin dosing in 
a pediatric population. Nonetheless, this remains to be confirmed 
for our app-based dosing strategy in a larger prospective 
validation study. Lastly, this study has been performed at a single 
center, comprising of a multi-ethnic Asian cohort. In general, 
the geographical validity of vancomycin dosing models has 
been dismal (Murphy et al., 2006; Deng et al., 2013). This could 
reflect the need for setting-specific dosing aids for vancomycin 
given its narrow therapeutic window and need for nuanced dose 
adjustments; however, a formal study of our app-based dosing in 
an external setting in future would need to be carried out to assess 
its generalizability.
Precise vancomycin dosing is important to maximize treatment 
success in patients with CKD. Yet CKD alters vancomycin 
pharmacokinetics, making precise dosing a challenge. We 
report the derivation, validation, and postimplementation 
evaluation of a vancomycin dosing application (VancApp) for 
optimizing dosing decisions in patients with CKD. Patients who 
had received VancApp-based doses had taken a shorter median 
time to attain target concentrations by one and a half days. 
While causality cannot be attributed in this nonrandomized 
study, corroborating trends were observed in terms of improved 
30-day mortality and 30-day readmission due MRSA infections 
in VancApp-dosed patients.
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